[ACCESSWIRE]
CORAL GABLES, FL / ACCESSWIRE / October 23, 2018 / This week has some of the most notable earnings reports being released for the quarter. Though the markets have pulled back from their previous highs, positive earnings have helped give a boost to certain sectors. Technology has been one of these sectors and more specifically, technology related to healthcare has captured new attention in the markets. Today, we're exploring 3 stocks to watch that are focusing on building their business in the health related markets including Premier Health Group, Inc. ( PHGRF)(PHGI.CN), Symbililty Solutions Inc. (TSX-V: SY.V)(OTC PINK: ATBEF), and CASI Pharmaceuticals, Inc. (NASDAQ: CASI).
Premier Health Group, Inc. (PHGRF)(PHGI.CN)’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and according to Premier Health, it plans to rapidly increase that number both domestically and internationally.
According to HealthVue, Approximately 15% of Canadians aged 12 and older don’t have a primary care physician. Nearly two-thirds (59%) of seniors are unable to get a same-or next-day appointment. Almost 7 in 10 Canadians avoid seeing a doctor when they are sick. With new access to things like the telemedicine technology that HealthVue offers, the technology allows users to see virtual HealthVue doctor through the telemedicine app/website (Government funded in BC, therefore no additional cost to the patient). Furthermore, prescriptions for users can be electronically submitted to the pharmacy of their choice or delivered free to them by a preferred pharmacy partner.
Premier Health Group, Inc. (PHGRF)(PHGI.CN), has managed to hit trading levels as high as CAD$0.88 this month. The company announced that just this week its common shares that are traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol " PHGRF," are now Depository Trust Company eligible. This was effective October 22, 2018 and allows Premier Health shares to be more easily and economically transferred between brokerage accounts electronically within the United States
For More Information On Premier Health Group, Click Here
Symbililty Solutions Inc. (TSX-V: SY.V)(OTC PINK: ATBEF) has traded higher today. CoreLogic (CLGX), a leading global provider of property information, insight, analytics and data-enabled solutions, recently announced the Company has entered into a definitive agreement to acquire the outstanding shares of Symbililty Solutions Inc. (SY.V) not already owned by CoreLogic. CoreLogic currently holds approximately a 28% ownership interest in Symbility.
"Symbility expands our footprint in property and casualty insurance domestically and in key markets around the globe. Further scaling our insurance and international footprint offers the potential for significant non-cyclical growth in line with our long-term goal of sourcing at least 50% of our revenues from non-U.S. mortgage. In addition to the obvious financial benefits and synergies, the combination of CoreLogic and Symbility should yield significant future growth opportunities through the introduction of new products, services and workflow tools which draw from a wide range of unmatched gold-standard data assets, platforms and analytical capabilities," said Frank Martell, President and Chief Executive Officer of CoreLogic.
For More Information On Symbility, Click Here
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) has also rallied on Tuesday. The company is a biopharmaceutical company focused on the acquisition, development, and commercialization of quality pharmaceuticals and innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on greater China and the U.S
CASI’s product portfolio includes (1) EVOMELA® (melphalan) for injection, MARQIBO®, (vinCRIStine sulfate LIPOSOME injection), ZEVALIN®, (ibritumomab tiuxetan), all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights that are currently in various stages in the regulatory and clinical process for market approval in China, (2) ENMD-2076 (Phase 2) (3) entecavir for hepatitis B and the other U.S. ANDA products, (4) CASI-001 and CASI-002, proprietary immuno-oncology preclinical candidates.
CASI announced today that it that has acquired a U.S. FDA-approved abbreviated new drug application (ANDA) from Laurus Labs Limited. The drug, tenofovir disoproxil fumarate (TDF), is indicated for the treatment of hepatitis B virus (HBV).
Wei-Wu He, Ph.D., CASI's Executive Chairman commented, "The acquisition of this ANDA from Laurus enhances our robust and emergent pipeline and is consistent with our broader mission to commercialize U.S. FDA approved drugs in China. The regulatory landscape in China is rapidly evolving to provide patients with quicker and more affordable access to high-quality medicines and we believe CASI is well positioned with infrastructure and leadership to launch products from our ANDA portfolio rapidly and efficiently."
For More Information On CASI, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2018 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer
Contact Information:
[email protected]
SOURCE: StockPrice.com
